Matching-adjusted indirect comparison of tobramycin solution (TIS) versus aztreonam lysine (AZLI) using TIS patient level clinical trial data and AZLI aggregated clinical trial data from published literature.

Inclusion Criteria:

• ≥ 6 years of age with a documented Cystic fibrosis (CF) diagnosis,
• moderate-to severe lung disease,
• the ability to perform reproducible pulmonary function tests,
• Pseudomonas aeruginosa (PA) airway infection.

Exclusion Criteria:

Other protocol-defined inclusion/exclusion criteria may apply.

Cystic fibrosis